{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderately+to+Severely+Active+Crohn+Disease",
    "query": {
      "condition": "Moderately to Severely Active Crohn Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 97,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderately+to+Severely+Active+Crohn+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T13:12:42.324Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04173273",
      "title": "A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Etrasimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 379,
      "start_date": "2020-01-06",
      "completion_date": "2025-06-09",
      "has_results": true,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-10-05T13:12:42.324Z",
      "location_count": 192,
      "location_summary": "Dothan, Alabama • Mobile, Alabama • Peoria, Arizona + 62 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04173273"
    },
    {
      "nct_id": "NCT03759288",
      "title": "An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease",
        "IBD"
      ],
      "interventions": [
        {
          "name": "Brazikumab low dose",
          "type": "DRUG"
        },
        {
          "name": "Brazikumab high dose",
          "type": "DRUG"
        },
        {
          "name": "Humira®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 89,
      "start_date": "2018-12-07",
      "completion_date": "2023-10-18",
      "has_results": true,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-10-05T13:12:42.324Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Lancaster, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03759288"
    },
    {
      "nct_id": "NCT03961815",
      "title": "Open-label Extension Study of Brazikumab in Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease",
        "IBD"
      ],
      "interventions": [
        {
          "name": "Brazikumab Induction Dose",
          "type": "DRUG"
        },
        {
          "name": "Brazikumab Maintenance Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 18,
      "start_date": "2020-01-06",
      "completion_date": "2023-09-19",
      "has_results": true,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-10-05T13:12:42.324Z",
      "location_count": 10,
      "location_summary": "Lincoln, California • Clearwater, Florida • Kissimmee, Florida + 6 more",
      "locations": [
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03961815"
    },
    {
      "nct_id": "NCT06764615",
      "title": "A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease",
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Zasocitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 192,
      "start_date": "2025-05-28",
      "completion_date": "2029-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-05T13:12:42.324Z",
      "location_count": 2,
      "location_summary": "Glen Burnie, Maryland • Tyler, Texas",
      "locations": [
        {
          "city": "Glen Burnie",
          "state": "Maryland"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06764615"
    },
    {
      "nct_id": "NCT06456593",
      "title": "Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Moderately to Severely Active Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Obefazimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Abivax S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 212,
      "start_date": "2024-10-30",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-10-05T13:12:42.324Z",
      "location_count": 43,
      "location_summary": "Fairhope, Alabama • Scottsdale, Arizona • Sun City, Arizona + 40 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06456593"
    },
    {
      "nct_id": "NCT04673357",
      "title": "A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 101,
      "start_date": "2021-04-06",
      "completion_date": "2025-03-03",
      "has_results": true,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-05T13:12:42.324Z",
      "location_count": 9,
      "location_summary": "Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04673357"
    },
    {
      "nct_id": "NCT03926130",
      "title": "A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Mirikizumab",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "15 Years to 80 Years"
      },
      "enrollment_count": 1158,
      "start_date": "2019-07-23",
      "completion_date": "2023-10-02",
      "has_results": true,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-10-05T13:12:42.324Z",
      "location_count": 140,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 113 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03926130"
    },
    {
      "nct_id": "NCT01817972",
      "title": "Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Certolizumab pegol",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Azathioprine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gastroenterology Research of America",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 65,
      "start_date": "2013-03",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2013-03-26",
      "last_synced_at": "2026-10-05T13:12:42.324Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01817972"
    },
    {
      "nct_id": "NCT02513459",
      "title": "A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Risankizumab 600 mg IV",
          "type": "DRUG"
        },
        {
          "name": "Risankizumab 180 mg SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 65,
      "start_date": "2015-09-16",
      "completion_date": "2019-06-19",
      "has_results": true,
      "last_update_posted_date": "2020-04-24",
      "last_synced_at": "2026-10-05T13:12:42.324Z",
      "location_count": 2,
      "location_summary": "Chevy Chase, Maryland • Chesterfield, Michigan",
      "locations": [
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        },
        {
          "city": "Chesterfield",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02513459"
    },
    {
      "nct_id": "NCT02877134",
      "title": "Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "JNJ-64304500",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 388,
      "start_date": "2016-08-25",
      "completion_date": "2022-01-24",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-05T13:12:42.324Z",
      "location_count": 37,
      "location_summary": "Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more",
      "locations": [
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02877134"
    }
  ]
}